Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease

Adriana Diaconu, Bogdan-Ioan Coculescu, Gheorghe Manole, Horăiu Vultur, Elena Claudia Coculescu, Cristina Maria Stocheci, Ioan-Sorin Tudorache, Alexandra-Ligia Dincă and Valeriu Gabi Dincă

Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Faculty of Medicine, Titu Maiorescu University, Bucharest, Romania; Center for Military Medical Scientific Research, Bucharest, Romania; Colentina Clinical Hospital, Bucharest, Romania; Faculty of Dental Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; Faculty of Sciences, University of Pitești, Pitești, Romania; Medicover Hospital, Bucharest, Romania

ABSTRACT

In a group of 208 patients with chronic ischaemic heart disease, the variation of A2-associated-LDL phosphatase (Lp-PLA2) serum concentration values was analysed in dynamics at a two-week interval. The conclusion of the study is that the values of serum concentration of Lp-PLA2 can be accepted as a biomarker with diagnostic specificity for chronic ischaemic heart disease, a parameter of real utility in medical practice, both in situations where the patient, although clinically reporting the existence of angina pectoris, does not show specific changes on an EKG, and for the assessment of the response to personalised therapy.

Introduction

Globally, the goals of cardiovascular disease research after the start of the current millennium are to identify simple or complex disease-specific markers that can be used to predict risk in atherosclerosis. Regardless of the clinical form of the disease under which it is expressed, research in atherosclerosis with coronary localisation is focused on the study of parameters and processes that provide data on the relationship with: inflammation, intracellular signalling, cardiovascular remodelling, apoptosis and similar cardiomyocyte death processes. At the level of the hypoxic myocardium, the development of such processes under the action of locally developed oxidative stress presupposes as a first stage the alteration of the existing fluidity at the level of the proteophospholipid layers in the membrane constitution. The process involves, as a first stage, the peroxidation of membrane ceramides generating hydroperoxides which, acting on membrane proteins, modify their physical properties, including the orientation and dynamics of constitutional phospholipids. An essential contributor is the flow of phospholipids from the deep layers of the membrane to the outer membrane, a flow subsequently compensated by a balancing on both sides.

The structural-functional integrity of cells is dependent on the maintenance of redox homeostasis, as redox systems develop modulation effects on the signalling cascade at the cellular level. In the conditions of redox homeostasis disorder, regardless of the type of cells, the way they respond depends on the intensity of the oxidative stress, but also on its anti-oxidant defence capacity. To maintain redox homeostasis, in case of excessive increase in intracellular ROS/RNS concentration, modulatory mechanisms that develop antioxidant activity or reduce the processes induced by oxidative stress are used. Their efficiency expresses the degree of stimulation of the genes that induce the synthesis of enzymes recognised as developing such actions. Similarly to what occurs in any cell exposed to oxidative stress and cardiomyocytes, the development of processes is mediated by the activation of serine-lipase enzymes located in their membranes or cytosol, but also secreted by some migrated cells at the level of myocardium, such as: monocytes/macrophages, T lymphocytes and mast cells. At their level, oxidative stress causes the activation of PLA2 and C-type enzymes in the structure of the membranes or the cytosol of the myocardial fibre. The PLA2 superfamily comprises of 19 members, of which at least 13 have been identified with certainty. Important are the isozymes belonging to the secretory PLA2 (sPLA2), cytosolic PLA2 (cPLA2/PLA2 group IV) and calcium-independent PLA2 (iPLA2) groups. It is accepted that approximately 80% of PLA2 circulates bound to low-density lipoprotein (LDL) and only 20% binds to high-density lipoprotein (HDL) or other circulating lipoprotein fractions. The role of the lipoprotein component in the sPLA2 complex is unknown, but X-ray studies have shown that in this form the enzyme is much more active by binding to the layers of membrane phospholipids or to mycelium. Coupling the substrate to the active site of the membrane-bound enzyme may have different structural-functional consequences, because after the release of the ester bond from the sn-2 position of the oxidised glycerophospholipids and the release of the arachidonic acid, under catalytic action it becomes

CONTACT Bogdan-Ioan Coculescu, bogdancoculescu@yahoo.fr, Faculty of Medicine, Titu Maiorescu University, 67A Gheorghe Petrașcu, Bucharest, Romania. All authors contributed equally to this work

© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Figure 1. The involvement of PLA2 in the process of peroxidation of membrane lipids; the synthesis of the main mediators initiating inflammation in atherogenesis.

FLAP: 5-lipoxygenase-activating protein; 5-HPETE: 5-hydroperoxyeicosatetraenoic acids; HETE: hydroxyeicosatetraenoic acids; cPLA2: cytosolic phospholipases A2 cytosolic; PLC: phospholipase C; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3: phosphatidylinositol; DAG: diacylglycerol; PKC: protein kinase C; ACT: acyltransferases; PG: prostaglandins; LT: leukotrienes; lyso-PAF: alkyl homolog PAF; PAF: platelet-activating factor (receptor); LOX: lipoxygenases; MAPK: MAP-kinases (MEK, ERK), mitogen-activated protein kinase; c GMP: Guanosine monophosphate 3',5'-cyclic.
a precursor of eicosanoids, generating biologically active com-

pounds\textsuperscript{14–19} (Figure 1).

From the previous figure, the processes of translocation and activation of PL\(_A\) and the synthesis of prostaglandins (PG), leuko-

trienes (LTs) and lysophospholipids\textsuperscript{20} are highlighted as “turntables” in the development of atherosclerosis. The resulting com-

pounds activate, sequentially, various intracellular message transduction pathways, down to the nucleus level, developing the ini-

tiation and maintenance of the inflammatory process in athero-

sclerosis, including the one with coronary localisation\textsuperscript{21}. This allows us to claim that the Lp-PLA\(_2\) enzyme, which is pro-ather-

ogenic through its circulating concentrations, provides the medick, indirectly, with information about the amplitude of the athero-

sclerotic processes.

The effects mentioned are the result of the regional presence of oxidative stress, but also of endothelin (ET) which, when associ-

ated, develops a potentiating role. In optimal tissue concentra-

tions, this does not develop action on the normal heart, but when present at high values it develops complex effects, mediated in autocrine or paracrine ways, depending on the subtype of the activated membrane receptors. The action is possible because car-

diomcyctes express both types of endothelin receptors: ET\(_A\) and ET\(_B\). At the level of the myocardium that works in optimal irriga-

tion conditions (physiological conditions), the first type of recep-

tors is predominant, so that in conditions of tissue hypoxia the ET\(_B\) subtype is overexpressed, which explains the effects of endo-

thelin delaying the diastolic relaxation of the myocardium, cardio-

myocyte hypertrophy, interstitial fibrosis, and induction of certain foetal patterns of gene expression responsible for cytoprotection, apoptosis, or necrosis\textsuperscript{22,23}. The scientific support for claiming such actions are developed by endothelin is represented by the results of determinations that showed in the hypertrophied or hemo-
dynamically overloaded myocardium a rich representation of the endothelin system, because the optimal oxygen requirement is not offered. What is still unknown is whether ET in myocardial excess is produced only by atherosclerotically affected coronary endothelial cells, or if it is also the result of excessive synthesis and secretion at the myocardial fibre level \textsuperscript{22,24}. An argument in support of this last action is the results of studies that have shown that the plasma level of endothelin increases progressively with the degree of cardiac decompensation. However, the answer to the question of whether endothelin hyper-synthesis occurs as a compensatory mechanism or, on the contrary, is one that precipi-
tates the development of myocardial contractile function deficit remains unclear\textsuperscript{25}.

**Material and methods**

The study group consisted of 208 patients (147 men and 61 women, respectively) suffering from chronic ischaemic heart dis-

ease, excluding cases of acute myocardial infarction or sequelae.

The present study appoints as a prospective one following eth-

ical principles derived from the Declaration of Helsinki (Committee

on Human Investigation). The age limits were between 35 and 64 years, the average being 54.3 years (Figure 2).

In selecting the patients co-opted into the group, their weight was taken into account, relating it to the ideal one. The selection followed the instructions of the experts of the National Institute of Health, from the WHO report published in 1989, by calculating the value of body mass index (BMI), based on the calculation for-

mula:

\[
\text{BMI} = \frac{\text{Body weight expressed in kg}}{\text{height}^2} = \frac{\text{Kg}}{\text{m}^2}.
\]

Only patients with chronic ischaemic heart disease falling into the first three weight classes were included in the group, so not the obese.

In order for the patients in the study to have relatively the same diet and lifestyle, the patients were hospitalised for a period of 2 weeks, during which time they received the same diet and identical coronary dilating and lipid-lowering medication. Patients in the study were given exact doses of circulating levels of Lp-PLA\(_2\).

The dosage of Lp-LPA\(_2\) serum was determined both at admis-

sion and at discharge on the 14th day. Depending on when the determination was made, the following were calculated for the whole batch:

- medium serum concentration on the first day of hospitalisation;
- medium serum concentration on the last day of hospitalisation (the 14\textsuperscript{th} day);

Subsequently, using the two average values that were calcu-

lated, a third parameter was admitted - the average serum concen-
	ration of Lp-PLA2 per batch, regardless of the timing of the dosage. Mention: The procedure with two determinations instead of one was used in order to obtain a value as true as possible for the medium serum concentration/batch, but also to be able to appreciate the effect of the established therapy on the value of the serum concentrations of the studied parameters.

The principle of the method of determination: Lp-PLA\(_2\) hydroly-

ses the ester group at position 2 of the substrate [1-myristoyl-2-

(p-nitrophenyl)succinyl] phosphatidylcholine, releasing p-nitrophe-

nylsuccinate, a compound which in an aqueous solution releases p-nitrophenol. The concentration of p-nitrophenol released is measured spectrophotometrically and is directly proportional to the activity of the enzyme. Spectrophotometric measurements were performed at 405 nm and 505 nm. The variation of the absorption per minute is used to calculate the enzymatic activity. The results were expressed in IU/L (\text{\mu mols/min/L}).
Results

a. In the studied group, regardless of sex, the values of the average serum concentration of Lp-LPA2 calculated based on the values of the determinations performed at hospitalisation, discharge and the whole group (regardless of the time of determinations) are shown in the following Table (Table 2).

b. The incidence of the increased medium concentration of Lp-LPA2-emy per the whole group, regardless of the time of determination was 163/208 patients, representing a percentage of 78.3 (Figure 3).

c. In relation to the sex of the patients, regardless of the time of collection, the incidence of hyper-LPA2 is distributed as follows:

| Classification | BMI (kg/m²) |
|----------------|-------------|
| Underweight    | <18.5       |
| Normal weight  | 18.51–24.99 |
| Overweight     | 25.0–29.99  |
| Obese          |             |
| Type I         | 30.0–34.99  |
| Type II        | 35.0–39.99  |
| Type III       | >40         |

d. Irrespective of the sex of the patients studied, the incidence of elevated Lp-LPA2 serum values calculated on the basis of inpatient determinations compared with the same parameter calculated at discharge on the basis of inpatient dosing shows the predominance of the former, including regarding circulating levels (Table 1, respectively Figure 5).

Discussion

In support of the opportunity of our study, to identify possible diagnostic biomarkers in ischaemic heart disease, come at least two of the current concerns about cardiovascular disease, such as:

a. Their epidemiology, in which atherosclerosis is a major public health disease, generating multiple other cardiovascular diseases, labelled in medical practice as complications from it. Of these, we appreciate that chronic ischaemic heart disease with its multiple forms of manifestation was selected based on sound arguments, if we consider the repercussions on the quality of life of the individual, and the economic cost to the family and society.

b. The quasi-permanent concern to identify biomarkers that would allow on the one hand the early evaluation of both atherosclerosis and especially of its various forms of clinical manifestation, in order to optimise the treatment, in order to delay the appearance of its severe forms.

Trying to respond to such a desire for patients already diagnosed with chronic ischaemic heart disease, we investigated possible clinical information that can provide us with medium serum values of Lp-LPA2 concentration, calculated based on collection times. For this purpose, we used their comparison with each other and with the one admitted as normal (Table 3).

In order to interpret the results of the mentioned comparisons, we resorted to determining the value of the p index, admitting the thresholds recorded in the literature as statistically representative.

1. Thus, the medium serum concentration of Lp-LPA2 in the component patients of the whole group calculated as a half-sum of the results of the dosages performed at admission and discharge, respectively, was 28.1% higher than the normal circulating value of the marker (Table 1). Statistically, the existing value difference allows us to admit that the serum value of Lp-PLA2 can be considered a biomarker for the diagnosis of chronic ischaemic heart disease, especially in clinical forms that cannot be certified by the results of other paraclinical examinations performed.

2. The study of the data from Table 1, respectively, Figure 1 highlights that, regardless of gender, the incidence of elevated values of the medium serum concentration calculated for the whole group, regardless of the time of determination of Lp-LPA2, is present in a percentage of 78.3, which allows us to propose the parameter as diagnostic biomarker of chronic ischaemic heart disease.

3. In support of the proposal that the serum level of Lp-PLA2 may be a possible risk biomarker in chronic ischaemic heart disease, the values of the average serum concentration of Lp-LPA2 calculated based on the values of the determinations performed at hospitalisation, discharge and the whole group (regardless of the time of determinations) are shown in the following Table (Table 2).

Table 1. Classification of calculation results.

| Classification | BMI (kg/m²) |
|----------------|-------------|
| Underweight    | <18.5       |
| Normal weight  | 18.51–24.99 |
| Overweight     | 25.0–29.99  |
| Obese          |             |
| Type I         | 30.0–34.99  |
| Type II        | 35.0–39.99  |
| Type III       | >40         |

Figure 4. The incidence of hyper-Lp-LPA2-emy in relation to the sex of patients in the studied group. a. Martor lot. b. Incidence of increased Lp-PLA2 in females, reported only in females. c. Incidence of Lp-PLA2 increase in females, reported in the entire control group. d. Incidence of male Lp-PLA2 increase, reported only in male cases. e. Incidence of male Lp-PLA2 increase, reported in the entire control group.
4. The study data led to a significant concordance of the increase in the average circulating level of Lp-PLA2 with that of its incidence, especially for men, which is why we postulate not only that the enzyme can be supported as a biomarker in chronic ischaemic heart disease, but also that it manifests specificity in relation to the patient's sex.

5. Related to the latter finding, in relation to the sex of the patients studied, the data showed that the incidence of hyper-Lp-PLA2-emy present in men is 2.1 times higher than that corresponding to women (Figure 4). In patients of the same sex, the incidence of increased hyper-Lp-PLA2-emy is 7 out of 10 women, and for men 8 out of 10, which means a value of the risk of developing serum growth of Lp-PLA2 substantially equal, i.e. unrelated to sex. We explain this by the composition of the study group, which in the sub-batch of women included mostly cases at climax and post-menopause. Through such a selection, the protective actions induced by oestrogen hormones were minimised.

6. We note that the conclusions of the study specified in points 3 and 4, according to which in men with chronic ischaemic heart disease there is a significant increase in Lp-PLA2 serum concentration, but which is not associated with an increase in incidence, i.e. sex-dependent, are not specified in the specialised literature. If we take into account the fact that in inter-current medical practice the interpretation of serum phospholipase concentrations is made by comparison with values admitted as normal, but which do not vary with the person's sex, we appreciate that through this study we generated a new possible research objective in the field, to identify whether or not there is a sex-related difference in enzyme serum values, even in healthy individuals.

At the same time, we recognise as a limitation of the study undertaken by us that for a real support of the highlighted specificity it is necessary to carry out research on quantitatively significant groups consisting of people considered healthy, respectively with chronic ischaemic heart disease.

7. The lipid-lowering and coronary dilator therapy instituted for the patients in the group led, at discharge, to the reduction of the medium circulating concentration of Lp-PLA2 compared to that dosed at admission with an approximate rate of 10%. We interpret the value of this quota as expressing the beneficial effect of the established therapy. Although it is a small reduction in the value of the average circulating concentration of Lp-PLA2, we appreciate that it correlates and expresses the results of the short therapy of the disease of only 2 weeks. Indirectly, we appreciate that the percentage reduction rate may be a motivation for a significant study in terms of duration of therapy and case series, in order to argue the possible proposal of Lp-PLA2 serum level also as a marker to assess the evolution of myocardial ischaemia under treatment, thus constituting a possible risk biomarker in this disease.

Conclusions

The conclusions of our study on patients with only chronic ischaemic heart disease lead to a high percentage of increased
circulating levels of Lp-PLA₂, but also its incidence, which is why we postulate that the enzyme can be supported as a biomarker in chronic ischaemic heart disease. The particular way of “behaviour” of the enzyme in the sub-batch of men opens the new direction of research to determine whether the serum value of Lp-PLA₂ depends on the sex of the patient, even in people considered healthy or if the serum behaviour of the enzyme has a specificity of sex only for chronic ischaemic heart disease.

At the same time, the study data allows us to make the assumption that the circulating level of Lp-PLA₂ can be evaluated as a possible biomarker of risk and assessment of the response to a certain type of lipid-lowering therapy instituted in patients with chronic ischaemic heart disease.

Disclosure statement

No potential conflict of interest was reported by the author(s).

ORCID

Bogdan-ioan Coculescu http://orcid.org/0000-0002-5375-272X

References

1. Dinca VG, Manole G, Dinca AL, et al. Considerations regarding the biomarker value of circulating concentration of PON₁ in patients with heart failure through chronic ischemic cardiomyopathy. J Environ Prot Ecol 2016;17:1563–74.
2. Aursulesei V, Crisu D, Cozma A, Datcu MD, Significance of new biomarkers in heart failure: from theory to clinical practice. Advances in Cardiology. Sfântu Gheorghe (Romania): T₃ Info SRL Publishing; 2009. Romanian.
3. Coculescu BI, Manole G, Dinčă VG, et al. Osteopontin – a biomarker of disease, but also of stage stratification of the functional myocardial contractile deficit by chronic ischaemic heart disease. J Enzyme Inhib Med Chem 2019;34:783–8.
4. Coculescu BI, Manole G, Dinca AL, et al. The possible serum complex-biomarkers for the early diagnosis of diastolic dysfunction with preserved systolic function. Rev Chim (Bucharest) 2019;70:2292–31.
5. Manole G, General clinical pathophysiology. Pathophysiology organs. Bucharest (Romania): National Company Printers, Coresi S.A. Publishing; 2003. Romanian.
6. Mohora M. Oxidative-mediated activity of phospholipase A2. EMCB. 2002. Available from: https://www.emcb.ro/article.php?story=20021113221552000 [last accessed 21 Jun 2020]. Romanian.
7. Coculescu BI, Manole G, Coculescu EC, et al. Autophagy as a neuronal survival mechanism in ischemic stroke. Rom J Leg Med 2018; 26:333–9.
8. Dinca VG, Dinca AL, Capitanescu C, Manole G. Cardiomyocyte membrane pathogenetic mechanisms and biochemical-induced endothelial-coronare in chronic ischamic heart disease. Int J Curr Res 2017;9:48435–9.
9. Santarpia L, Lippman LS, El-Naggar KA. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:103–19.
10. Coculescu BI, Dinčă GV, Bălaet C, et al. Myeloperoxidase, a possible biomarker for the early diagnosis of cardiac diastolic dysfunction with preserved ejection fraction. J Enzyme Inhib Med Chem 2018;33:1292–8.
11. Dröge W. Free radicals in the physiological control of cell function. Physiol Reviews 2002; 82:47–95.
12. Capitanescu A, Turculet CS, Capitanescu C, et al. Assessment of uncertainties in measurement of phospholipase A₂ activity from Vipera Ammodytes venom. Rev Roum Chim 2008; 53:329–37.
13. Leitinger N, Watson AD, Hama SY, et al. Role of group II secretory phospholipase A₂ in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids. Arterioscler Thromb Vasc Biol 1999;19:1291–8.
14. Murakami M, Kudo I. Phospholipase A₂. J Biochem 2002;131:285–92.
15. Cojocaru M, Cojocaru IM, Silosi I. Lipoprotein-associated phospholipase A₂ as a predictive biomarker of subclinical inflammation in cardiovascular diseases. Maedica J Clin Medicine 2010;5:51–5.
16. Tatulian SA. Toward understanding interfacial activation of secretory phospholipase A₂ (PLA₂): membrane surface properties and membrane-induced structural changes in the enzyme contribute synergistically to PLA₂ activation. Biophys J 2001; 80:789–800.
17. Gelb MH, Cho W, Wilton DC. Interfacial binding of secreted phospholipases A₂: more than electrostatics and a major role for tryptophan. Curr Opin Struct Biol 1999;9:428–32.
18. Sartipy P, Camejo G, Svensson L, Hurt-Camejo E. Phospholipase A₂ modification of low density lipoproteins forms high density small particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999; 274:25913–20.
19. Szmitko EP, Wang CH, Weisel DR, et al. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003;108:2041–8.
20. Dennis AE. Phospholipase A₂ in eicosanoid generation. Am J Respir Crit Care Med 2000;161:S32–535.
21. Heller A, Koch T, Schmeck J, van Ackern K. Lipid mediators in inflammatory disorders. Drugs 1998;55:487–96.
22. Colucci SW. Myocardial endothelin. Does it play a role in myocardial failure? Circulation 1996;93:1069–72.
23. Girotti WA. Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 1998;39: 1529–42.
24. Kitzman DW. Diastolic heart failure in the elderly. Heart Fail Rev 2002;7:17–27.
25. Coculescu BI, Harsovescu T, Tudorache IS, Manole G. PON-1, possible biomarker for diagnosis but also for risk in diastolic dysfunction with preserved ejection fraction. Rev Chim (Bucharest), 2019;70:1210–4.
26. Bălaet C, Coculescu BI, Manole G, et al. Gamma-glutamyl-transferase, possible novel biomarker in colon diverticulosis: a case-control study. J Enzyme Inhib Med Chem 2018;33:428–32.
27. Moldovan C, Dobrescu L, Ristoiu V, et al. Experimental measurements in the acquisition of biosignals from a neuronal cell culture for an exoprosthesis command. Rev Chim (Bucharest) 2018;69:2948–52.